To our knowledge, this is the first study to reveal the association between PKMYT1 activation and resistance to a nucleoside analog and to identify that resistant cells are especially sensitive to drug targeting this protein, suggesting that PKMYT1 might be a promising target for lung cancer treatment. This evidence concerns the gene PKMYT1 and lung carcinoma.